Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
This marks a meaningful step in the company's continued expansion in the region
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Subscribe To Our Newsletter & Stay Updated
